Eikon Therapeutics Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Eikon Therapeutics Inc. concentrates primarily on oncology, advancing a pipeline of product candidates designed to target difficult-to-treat cancers and other solid tumors. Its current programs include antibody-free and small-molecule therapies that act on pathways such as immune activation, DNA repair, and androgen receptor signaling. The company also uses a proprietary drug discovery platform that combines super-resolution microscopy, automation, data science, machine learning, and software engineering to study protein behavior in living cells and guide target identification. Headquartered in Millbrae, California, Eikon Therapeutics Inc. plays a role in the biopharmaceutical market by translating advanced biology and engineering into clinical-stage therapeutic development.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$322M
▼ -33.0% YoY
Op. Margin
–
ROIC
-116.48%
▲ +59.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$259M
▼ -7.1% YoY
Op. Cash Flow (TTM)
-$256M
▼ -36.0% YoY
Net Debt
-$79M
Net Cash Position
Cash & Equiv.
$336M
Continue Research
Peers
Biotechnology · Pick stocks to compare with EIKN
Held by ETFs
EIKN is in 7 US ETFs. The largest of them, with EIKN's weight in each:
Eikon Therapeutics (EIKN) in three numbers
Questions about Eikon Therapeutics
Is Eikon Therapeutics a high-quality business?
Eikon Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$79M, and its weakest is return on capital at -116.5%. The Quality tab shows every check against its target.
Does Eikon Therapeutics (EIKN) pay a dividend?
No. Eikon Therapeutics (EIKN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing EIKN
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.